Resumen

Este es un estudio abierto, multinacional, aleatorizado de Fase 2 que confirma el beneficio clínico de futibatinib 20 mg y evalúa la seguridad y eficacia de futibatinib 16 mg en pacientes con CCA previamente tratados que presentan fusiones génicas de FGFR2 y otros reordenamientos.

Descripción detallada

Este es un estudio abierto, multinacional, aleatorizado de Fase 2 que confirma el beneficio clínico de futibatinib 20 mg y evalúa la seguridad y eficacia de futibatinib 16 mg en pacientes con CCA previamente tratados que presentan fusiones génicas de FGFR2 y otros reordenamientos. Los pacientes elegibles serán aleatorizados en proporción 1:1 a los siguientes brazos del estudio: * Los pacientes recibirán futibatinib por vía oral a una dosis de 16 mg, administrado una vez al día (QD) todos los días de un ciclo de 21 días. * Los pacientes recibirán futibatinib por vía oral a una dosis de 20 mg, administrado una vez al día (QD) todos los días de un ciclo de 21 días. Los pacientes podrán continuar recibiendo futibatinib de forma continua hasta la documentación de enfermedad progresiva (EP) según RECIST 1.1, o hasta que se cumplan otros criterios de retirada, lo que ocurra primero.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Histologically or cytologically confirmed, locally advanced, metastatic, or unresectable intrahepatic of extrahepatic Cholangiocarcinoma.
Documented evidence of FGFR2 gene fusions or other FGFR2 rearrangement
Received at least one prior systemic gemcitabine and platinum-based regimen for CCA
Documentation of radiographic disease progression on the most recent prior therapy
Measurable disease
performance status 0 or 1
Adequate organ function

Criterios de exclusión

History or current evidence of calcium and phosphate homeostasis disorder
Current evidence of clinically significant retinal disorder
Treatment with any of the following within the specified time frame prior to the first dose of futibatinib:
Major surgery within the previous 4 weeks (the surgical incision should be fully healed prior to the first dose of futibatinib) and radiotherapy for extended field within 4 weeks or limited field radiotherapy within 2 weeks
Patients with locoregional therapy, eg, transarterial chemoembolization (TACE), selective internal radiotherapy (SIRT) or ablation within 4 weeks
Any non investigational anticancer therapy within 3 weeks or have not recovered from side effects of such therapy prior to futibatinib. Endocrine therapy is allowed for patients with breast or prostate cancer
Targeted therapy or immunotherapy within 3 weeks or within 5 half lives Any investigational agent received within 5 half-lives of the drug or 4 weeks, whichever is shorter.
Patients with prior FGFR-directed therapy
A serious illness or medical condition(s) including (but not limited to) the following:
Known brain metastasis (not including primary brain tumors) unless patient is clinically stable for ≥1 month
Known acute systemic infection
Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure (New York Heart Association \[NYHA\] Class III or IV New York Heart Association \[NYHA\] Classification) within the previous 2 months; if \>2 months, cardiac function must be within normal limits and the patient must be free of cardiac-related symptoms
Significant gastrointestinal disorder(s) that could interfere with the absorption of futibatinib.
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the judgment of the Investigator would make the patient inappropriate for entry into this study.
Known additional malignancy that is progressing or requires active treatment, with the exception of patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or antitumor assessment of the investigational regimen. Exceptions must be discussed with the Sponsor prior to patient enrollment.
Pregnant or lactating female.
Known hypersensitivity or severe reaction to futibatinib or its excipients.

Intervenciones

drug

TAS-120

TAS-120 is an oral FGFR inhibitor

Ubicaciones

Hospital Britanico

Buenos Aires, Argentina

RECRUITING

CEMIC

CABA, Argentina

RECRUITING

Sanatorio de la Mujer

Rosario, Argentina

RECRUITING

Patrocinadores

PrincipalTaiho Oncology, Inc.

Contactos

Taiho Oncology, INC

CONTACT

medicalinformation@taihooncology.com +1 844-878-2446

Estudio de Fase 2 de Futibatinib 20 mg y 16 mg en Pacientes con Colangiocarcinoma Avanzado con Fusiones o Reordenamientos de FGFR2

Resumen

Descripción detallada

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

TAS-120

Ubicaciones

Hospital Britanico

CEMIC

Sanatorio de la Mujer

Patrocinadores

Contactos

Taiho Oncology, INC